Drug intelligence / Profile preview

CBP-246

Development stage: Discontinued
Lead developer: Connect Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CBP-246 is a monoclonal antibody that targets the interleukin-1 receptor accessory protein (IL-1RAcP), acting as an inhibitor of this protein. It was developed by Suzhou Connect Biopharma and is designed to modulate type 2 inflammatory diseases by blocking IL1RAP-mediated signaling pathways. The drug was in preclinical development for inflammation and other type 2 inflammatory conditions but has since been discontinued[1][4][10].

Targets

IL1RAP (Interleukin 1 receptor accessory protein)

Beyond the preview

Go deeper on CBP-246.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBP-246.

Explore the full profile